Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 58 clinical trials
A Phase 1B Study of RP1 in Transplant Patients With Advanced Cutaneous Squamous Cell Carcinoma

This Phase 1B study is a multicenter, open-label, study of RP1 to investigate the safety and tolerability of RP1 for the treatment of advanced CSCC in up to 30 evaluable organ transplant recipients. This will include patients with either previous renal or hepatic allograft transplantation and experiencing subsequent documented locally …

organ transplantation
  • 0 views
  • 28 Jan, 2021
  • 4 locations
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck

Current guidelines in management of regional lymph node metastases for cSCC patients include surgical resection with or without adjuvant therapy as well as chemotherapy and interdisciplinary management; in advanced disease, supportive and palliative care is recommended. These guidelines also define the role of SLNB in management of high-risk cSCC as …

  • 0 views
  • 27 Jan, 2021
  • 1 location
Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery

To determine the histopathological response rate to neo-adjuvant nivolumab and nivolumab plus ipilimumab at time of standard of care(surgery radiotherapy).in patients with cutaneous squamous

  • 0 views
  • 26 Jan, 2021
  • 1 location
Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

The primary objective of the study is to evaluate the efficacy of neoadjuvant cemiplimab as measured by Pathologic complete response (pCR) rate per independent central pathology review. The secondary objectives of the study are: To evaluate the efficacy of neoadjuvant cemiplimab on measures of disease response, including Major pathologic response …

skin cancer
cemiplimab
local pathology review
cancer
  • 0 views
  • 26 Jan, 2021
  • 22 locations
Cemiplimab in AlloSCT/SOT Recipients With CSCC

In this research study, Cemiplimab is being evaluated as a treatment for advanced cutaneous squamous cell carcinoma in participants who have previously received an allogeneic hematopoietic stem

squamous cell carcinoma
prednisone
cemiplimab
sirolimus
acute gvhd
  • 0 views
  • 25 Jan, 2021
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic CSCC, as assessed by overall response rate (ORR) according to central review.

skin cancer
cemiplimab
cancer
  • 2 views
  • 28 Jan, 2021
  • 23 locations
Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC

The purpose of this research study is to determine how people with weakened immune systems and unresectable (cannot be removed by surgery) locally recurrent and/or metastatic cutaneous squamous

metastasis
cancer
cemiplimab
multiple myeloma
metastatic cutaneous squamous cell carcinoma
  • 0 views
  • 27 Jan, 2021
  • 1 location
Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

This phase I trial studies how well cemiplimab before and after surgery works in treating patients with high risk cutaneous squamous cell cancer. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow …

  • 0 views
  • 24 Jan, 2021
Immunotherapy With IFx-Hu2.0 Vaccine for Advanced MCC or cSCC

cutaneous squamous cell carcinoma (cSCC) will receive a fixed dose of 0.1 mg of IFx-Hu2.0 intralesionally as monotherapy in up to three lesions at up to three time points. Subjects will be observed for any

measurable disease
platelet count
metastasis
tubal ligation
merkel cell carcinoma
  • 2 views
  • 24 Jan, 2021
  • 2 locations
Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

This is a phase I study, which tests the safety of different doses of lenvatinib in combination with cetuximab, to see which dose is the safest in people. This study will help find out if lenvatinib and cetuximab is a safe and useful combination for treating patients with HNSCC and …

dental caries
squamous cell carcinoma
antihypertensive
lenvatinib pill
carcinoma
  • 16 views
  • 23 Jan, 2021
  • 8 locations